MCMathieu Coincon

Mathieu Coincon

*This is an algorithmically generated author record based on publicly available information.

Mathieu Coincon has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Visualizing drug inhibitor binding interactions using microcrystal electron diffraction

    by Max T.B. Clabbers, S. Zoë Fisher, Mathieu Coinçon, Xiaodong Zou, Hongyi Xu

    Visualizing drug inhibitor binding interactions at the atomic level is important for both structure-based drug design and fragment-based screening methods. Rapid and uniform soaking with potentially less lattice defects make small macromolecular crystals attractive targets for studying ligand biding using 3D microcrystal electron diffraction (MicroED). However, so far no drug inhibitor binding interactions could unambiguously be resolved by electron diffraction. Here, we use MicroED to study the binding of a sulfonamide inhibitor to human carbonic anhydrase isoform II (HCA II). We show that MicroED data can efficiently be collected in-house on a conventional TEM from thin hydrated microcrystals after a brief soaking with the clinical drug inhibitor acetazolamide (AZM). The data are of high enough quality to unequivocally fit and resolve the inhibitor bound to the active site of the protein. We anticipate MicroED can play an important role in future drug discovery experiments, complementing existing methods in structural biology such as x-ray and neutron diffraction.


  • Structural basis for the delivery of activated sialic acid into Golgi for sialyation

    by Emmanuel Nji, Ashutosh Gulati, Abdul Aziz Qureshi, Mathieu Coincon, David Drew

    The decoration of secretory glycoproteins and glycolipids with sialic acid is critical to many physiological and pathological processes. Sialyation is dependent on a continuous supply of sialic acid into Golgi organelles in the form of CMP-sialic acid. Translocation of CMP-sialic acid into Golgi is carried out by the CMP-sialic acid transporter (CST). Mutations in human CST are linked to glycosylation disorders, and CST is important for glycopathway engineering, as it is critical for sialyation efficiency of therapeutic glycoproteins. The mechanism of how CMP-sialic acid is recognized and translocated across Golgi membranes in exchange for CMP is poorly understood. Here we have determined the crystal structure of a Zea mays CST in complex with CMP. We conclude that the specificity of CST for CMP-sialic acid is established by the recognition of the nucleotide CMP to such an extent that they are mechanistically capable of both passive and coupled antiporter activity.


  • Open Access

    Integrating mass spectrometry with MD simulations reveals the role of lipids in Na+/H+ antiporters

    by Michael Landreh, Erik G. Marklund, Povilas Uzdavinys, Matteo T. Degiacomi, Mathieu Coincon, Joseph Gault, Kallol Gupta, Idlir Liko, Justin L. P. Benesch, David Drew, et al.

    Na+/H+ antiporters are found in all kingdoms of life and exhibit catalysis rates that are among the fastest of all known secondary-active transporters. Here we combine ion mobility mass spectrometry and molecular dynamics simulations to study the conformational stability and lipid-binding properties of the Na+/H+ exchanger NapA from Thermus thermophilus and compare this to the prototypical antiporter NhaA from Escherichia coli and the human homologue NHA2. We find that NapA and NHA2, but not NhaA, form stable dimers and do not selectively retain membrane lipids. By comparing wild-type NapA with engineered variants, we show that the unfolding of the protein in the gas phase involves the disruption of inter-domain contacts. Lipids around the domain interface protect the native fold in the gas phase by mediating contacts between the mobile protein segments. We speculate that elevator-type antiporters such as NapA, and likely NHA2, use a subset of annular lipids as structural support to facilitate large-scale conformational changes within the membrane.


  • Open Access

    Sent packing: protein engineering generates a new crystal form ofPseudomonas aeruginosaDsbA1 with increased catalytic surface accessibility

    by Roisin M. McMahon, Mathieu Coinçon, Stephanie Tay, Begoña Heras, Craig J. Morton, Martin J. Scanlon, Jennifer L. Martin

    Pseudomonas aeruginosais an opportunistic human pathogen for which new antimicrobial drug options are urgently sought.P. aeruginosadisulfide-bond protein A1 (PaDsbA1) plays a pivotal role in catalyzing the oxidative folding of multiple virulence proteins and as such holds great promise as a drug target. As part of a fragment-based lead discovery approach to PaDsbA1 inhibitor development, the identification of a crystal form of PaDsbA1 that was more suitable for fragment-soaking experiments was sought. A previously identified crystallization condition for this protein was unsuitable, as in this crystal form of PaDsbA1 the active-site surface loops are engaged in the crystal packing, occluding access to the target site. A single residue involved in crystal-packing interactions was substituted with an amino acid commonly found at this position in closely related enzymes, and this variant was successfully used to generate a new crystal form of PaDsbA1 in which the active-site surface is more accessible for soaking experiments. The PaDsbA1 variant displays identical redox character andin vitroactivity to wild-type PaDsbA1 and is structurally highly similar. Two crystal structures of the PaDsbA1 variant were determined in complex with small molecules bound to the protein active site. These small molecules (MES, glycerol and ethylene glycol) were derived from the crystallization or cryoprotectant solutions and provide a proof of principle that the reported crystal form will be amenable to co-crystallization and soaking with small molecules designed to target the protein active-site surface.